GLP1R and obesity due to melanocortin 4 receptor deficiency: Glucagon-like peptide-1 (GLP-1) receptor agonists have emerged as a pivotal class of medications primarily used in the treatment of type 2 diabetes mellitus (T2DM) and obesity [1, 2].